News

Commission has adopted main Horizon Europe Work Programme 2023-2024

Published on | 2 years ago

Programmes MSCA RI Health Culture and society Security Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment EIE Widening/Spreading Enhancing EU R&I Missions Horizon Europe HorizonEU L+F

The Commission has now adopted the ‘main’ Horizon Europe work programme 2023-2024, with around €13.5 billion to support researchers and innovators in Europe to pursue breakthrough solutions for environmental, energy, digital and geopolitical challenges. Read the full Press Release here.

The adopted work programme texts are available in pdf form on the Funding&Tenders Portal (under reference documents here). The calls, topics and actions are fully published and searchable on the Funding&Tenders Portal. The first calls are now open.

The call topics overview on the NCP Flanders website has already been updated accordingly and also contains an overview of open/forthcoming 2023-2024 call topics.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1530 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.